Home / Stocks / BMRN

BioMarin Pharmaceutical (BMRN, Biotechnology) Stock Valuation & Fair Value Fairly valued

BioMarin Pharmaceutical (BMRN, Biotechnology) trades at a blended P/E of 15.6, about 69% below its historical normal valuation, with a forward growth estimate of 33.7% and a PEG of 0.46. Priced at its historical normal P/E of 51.0 on the same blended earnings, the 2026-09-18 close of $63.94 corresponds to about $209 a share. This is a valuation reference, not a price target.

DATA AS OF 2026-09-21
Blended P/E
15.6
Normal P/E
51.0
PEG
0.46
Fwd growth
33.7%
Div yield
0.0%
RSI (14)
43.6
Neutral

The Street vs SeerForecast

Wall Street's mean price target for BMRN is $91.62 across 26 analysts, 47.3% above the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: fairly valued. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating moved from quality business with a solid forward outlook (2026-07-31) to fairly valued (2026-09-21).

Blended P/E and rating by weekBlended P/E moved from 16.8 to 15.6 between 2026-07-31 and 2026-09-21, against a normal P/E of 51.0, with 3 rating changes over 18 recorded weeks.2026-07-31: P/E 16.8, Quality business with a solid forward outlook (recalculated)2026-08-03: P/E 16.6, Quality business with a solid forward outlook2026-08-07: P/E 16.6, Quality business with a solid forward outlook (recalculated)2026-08-10: P/E 17.1, Fairly valued2026-08-14: P/E 17.1, Fairly valued (recalculated)2026-08-17: P/E 16.8, Quality business with a solid forward outlook2026-08-21: P/E 16.8, Quality business with a solid forward outlook (recalculated)2026-08-24: P/E 17.3, Fairly valued2026-08-27: P/E 17.3, Fairly valued (recalculated)2026-08-28: P/E 17.3, Fairly valued (recalculated)2026-08-30: P/E 17.3, Fairly valued (recalculated)2026-08-31: P/E 16.5, Fairly valued2026-09-05: P/E 16.5, Fairly valued (recalculated)2026-09-07: P/E 16.7, Fairly valued2026-09-12: P/E 16.7, Fairly valued (recalculated)2026-09-14: P/E 16.2, Fairly valued2026-09-19: P/E 16.2, Fairly valued (recalculated)2026-09-21: P/E 15.6, Fairly valued20.030.040.050.0Jul 31Aug 13Aug 26Sep 8Sep 21Normal P/E 51.0
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

Selected weeks: the first, the latest, every week the rating moved, and the cheapest and dearest.

WeekBlended P/EPremium to normal P/ERating
2026-07-31P/E 16.8-67%Quality business with a solid forward outlook
2026-08-10P/E 17.1-66%Fairly valued
2026-08-17P/E 16.8-67%Quality business with a solid forward outlook
2026-08-24P/E 17.3-66%Fairly valued
2026-09-21P/E 15.6-69%Fairly valued ← now

Frequently asked questions

Is BioMarin Pharmaceutical stock overvalued?

At a blended P/E of 15.6 versus its historical normal P/E of 51.0, BioMarin Pharmaceutical trades about 69% below its typical valuation, with a PEG of 0.46 on 33.7% forward growth. tickerseer currently rates it fairly valued.

What is BioMarin Pharmaceutical's fair value and PEG?

BioMarin Pharmaceutical trades at a blended P/E of 15.6 against a historical normal P/E of 51.0, a PEG of 0.46, and a forward growth estimate of 33.7%. Priced at its historical normal P/E of 51.0 on the same blended earnings, the 2026-09-18 close of $63.94 corresponds to about $209 a share. This is a valuation reference, not a price target.

Has tickerseer's rating of BioMarin Pharmaceutical changed?

tickerseer's rating moved from quality business with a solid forward outlook (2026-07-31) to fairly valued (2026-09-21).

What is the analyst price target for BioMarin Pharmaceutical?

The mean Wall Street price target for BioMarin Pharmaceutical is $91.62 across 26 analysts, 47.3% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Biotechnology. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track BMRN free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.